Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer

Breast Cancer Research and Treatment

Volumn 143, Issue 3, 2014, Pages 411-421

  Abdel Fatah, Tarek M A ^a   Perry, Christina ^a   Moseley, Paul ^a   Johnson, Kerstie ^a   Arora, Arvind ^a   Chan, Stephen ^a   Ellis, Ian O ^a   Madhusudan, Srinivasan ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

APE1; Biomarker; Breast cancer; DNA base excision repair

Indexed keywords

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DNA DAMAGE; DNA REPAIR; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; NEOPLASM GRADING; PROGNOSIS; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84894097784     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2820-7     Document Type: Article

References (32)

1. Yue W, Yager JD, Wang JP, Jupe ER, Santen RJ (2013) Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. Steroids 78(2):161-170. doi: 10.1016/j.steroids.2012.11.001
2. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R et al (2006) Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 1766(1):63-78. doi: 10.1016/j.bbcan.2006.03.001
3. Cavalieri EL, Rogan EG (2011) Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer. J Steroid Biochem Mol Biol 125(3-5):169-180. doi: 10.1016/j.jsbmb.2011.03.008
4. Gaikwad NW, Yang L, Muti P, Meza JL, Pruthi S, Ingle JN et al (2008) The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer 122(9):1949-1957. doi: 10.1002/ijc.23329
5. Lavigne JA, Goodman JE, Fonong T, Odwin S, He P, Roberts DW et al (2001) The effects of catechol-O-methyltransferase inhibition on estrogen metabolite and oxidative DNA damage levels in estradiol-treated MCF-7 cells. Cancer Res 61(20):7488-7494
6. Kim YJ, Wilson DM III (2012) Overview of base excision repair biochemistry. Curr Mol Pharmacol 5(1):3-13
7. Svilar D, Goellner EM, Almeida KH, Sobol RW (2011) Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. Antioxid Redox Signal 14(12):2491-2507
8. Abbotts R, Madhusudan S (2010) Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat Rev 36(5):425-435. doi: 10.1016/j.ctrv.2009.12.006
9. Tell G, Quadrifoglio F, Tiribelli C, Kelley MR (2008) The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal 11(3):601-620. doi: 10.1089/ars.2008.2194
10. Busso CS, Iwakuma T, Izumi T (2009) Ubiquitination of mammalian AP endonuclease (APE1) regulated by the p53-MDM2 signaling pathway. Oncogene 28(13):1616-1625
11. Demple B, Sung JS (2005) Molecular and biological roles of Ape1 protein in mammalian base excision repair. DNA Repair (Amst) 4(12):1442-1449
12. Wilson DM III, Barsky D (2001) The major human abasic endonuclease: formation, consequences and repair of abasic lesions in DNA. Mutat Res 485(4):283-307
13. Tang M, Pham P, Shen X, Taylor JS, O'Donnell M, Woodgate R et al (2000) Roles of E. coli DNA polymerases IV and V in lesion-targeted and untargeted SOS mutagenesis. Nature 404(6781):1014-1018
14. Yu SL, Lee SK, Johnson RE, Prakash L, Prakash S (2003) The stalling of transcription at abasic sites is highly mutagenic. Mol Cell Biol 23(1):382-388
15. Hadi MZ, Wilson DM III (2000) Second human protein with homology to the Escherichia coli abasic endonuclease exonuclease III. Environ Mol Mutagen 36(4):312-324
16. Bhakat KK, Mantha AK, Mitra S (2009) Transcriptional regulatory functions of mammalian AP-endonuclease (APE1/Ref-1), an essential multifunctional protein. Antioxid Redox Signal 11(3):621-638. doi: 10.1089/ARS.2008.2198
17. Fishel ML, Kelley MR (2007) The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med 28(3-4):375-395
18. Tell G, Damante G, Caldwell D, Kelley MR (2005) The intracellular localization of APE1/Ref-1: more than a passive phenomenon? Antioxid Redox Signal 7(3-4):367-384
19. Berquist BR, McNeill DR, Wilson DM III (2008) Characterization of abasic endonuclease activity of human Ape1 on alternative substrates, as well as effects of ATP and sequence context on AP site incision. J Mol Biol 379(1):17-27
20. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW (1992) Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 20(6):479-489
21. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403-410
22. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97(16):1180-1184
23. Sultana R, Abdel-Fatah T, Abbotts R, Hawkes C, Albarakati N, Seedhouse C et al (2013) Targeting XRCC1 deficiency in breast cancer for personalized therapy. Cancer Res 73(5):1621-1634. doi: 10.1158/0008-5472.CAN-12-2929
24. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118-145
25. Sultana R, McNeill DR, Abbotts R, Mohammed MZ, Zdzienicka MZ, Qutob H et al (2012) Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int J Cancer 131(10):2433-2444. doi: 10.1002/ijc.27512
26. Kakolyris S, Kaklamanis L, Engels K, Fox SB, Taylor M, Hickson ID et al (1998) Human AP endonuclease 1 (HAP1) protein expression in breast cancer correlates with lymph node status and angiogenesis. Br J Cancer 77(7):1169-1173
27. Zaky A, Busso C, Izumi T, Chattopadhyay R, Bassiouny A, Mitra S et al (2008) Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage. Nucleic Acids Res 36(5):1555-1566. doi: 10.1093/nar/gkm1173
28. Fung H, Bennett RA, Demple B (2001) Key role of a downstream specificity protein 1 site in cell cycle-regulated transcription of the AP endonuclease gene APE1/APEX in NIH3T3 cells. J Biol Chem 276(45):42011-42017. doi: 10.1074/jbc.M106423200
29. Kim K, Barhoumi R, Burghardt R, Safe S (2005) Analysis of estrogen receptor alpha-Sp1 interactions in breast cancer cells by fluorescence resonance energy transfer. Mol Endocrinol 19(4):843-854. doi: 10.1210/me.2004-0326
30. Curtis CD, Thorngren DL, Ziegler YS, Sarkeshik A, Yates JR, Nardulli AM (2009) Apurinic/apyrimidinic endonuclease 1 alters estrogen receptor activity and estrogen-responsive gene expression. Mol Endocrinol 23(9):1346-1359. doi: 10.1210/me.2009-0093
31. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS (2011) Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 10(8):1192-1199
32. Irshad S, Ashworth A, Tutt A (2011) Therapeutic potential of PARP inhibitors for metastatic breast cancer. Expert Rev Anticancer Ther 11(8):1243-1251. doi: 10.1586/era.11.52